This application of the Comprehensive Cancer Center of Wake Forest University (CCCWFU) requests renewal of its Cancer Center Support Grant for Years 33 through 37. During the current grant period, peer-reviewed annual direct cancer funding increased from $10.8 to $25.4 million, NCI funding increased from $5.1 to $12 million, and annual direct funding per member increased from $106,000 to $233,000. Interprogrammatic publications increased from 9.1% to 11.8%, intraprogrammatic publications increased from 16.7% to 28.6%, and interdepartmental publications increased from 17.4% to 28.7%. Formal collaboration (co-investigators, consultants, or collaborators) with other Cancer Center members is present on 68.5% of peer-reviewed research grants listed in summary II. In the current grant cycle we have made few structural changes, and instead focused on the execution of our scientific vision. Support is requested for four Programs: Cell Growth and Survival, DNA Damage and Cellular Defense, Clinical Research and Cancer Control as well as seven shared resources: Biomolecular Resource Laboratory, Cell Culture and Viral Vector, Microarray, Cellular Imaging, Tumor Tissue, Biostatistics, and Clinical Research Management. During this funding period, the CCCWFU opened a new 225,000 sq.ft. outpatient cancer center, and continued its longstanding focus and unique contributions to the cancer problems in our 7 state catchment area. The blueprint for our next five years is embodied in this application, which provides the Center's vision of how it can reduce the burden of cancer in our region and in the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-36S1
Application #
8322899
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-02-01
Project End
2012-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
36
Fiscal Year
2011
Total Cost
$74,984
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514

Showing the most recent 10 out of 548 publications